Small-molecule chromatin-modifying agents: Therapeutic applications

Epigenomics

Volumn 2, Issue 2, 2010, Pages 307-324

  Mai, Antonello ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

cancer; chromatin remodeling; epigenetics; histone deacetylase; infectious disease; neurodegenerative disease; sirtuin

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 PHENYLBUTYRIC ACID; ANILIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIMALARIAL AGENT; APICIDIN; BELINOSTAT; FLUOROURACIL; GIVINOSTAT; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMATINIB; MC 1568; MC 1575; MC 1714; MC 1716; MC 2113; MC 2211; MGCD 290; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; PYRROLE DERIVATIVE; PYRROLYL HYDROXAMATE; RETINOIC ACID; RETINOID DERIVATIVE; ROMIDEPSIN; SB 939; SIRTUIN; TAMOXIFEN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; WR 301801; WR 308292; WR 308298;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOID LEUKE; BREAST CANCER; CANDIDIASIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG MECHANISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; FRIEDREICH ATAXIA; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LYMPHOMA; MALARIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PARKINSON DISEASE; PERICARDITIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SOLID TUMOR;

ANILIDES; ANIMALS; ANTIFUNGAL AGENTS; ANTIMALARIALS; FURANS; GENE EXPRESSION REGULATION, VIRAL; HISTONE DEACETYLASE INHIBITORS; HIV-1; HUMANS; MICE; NEOPLASMS; NEURODEGENERATIVE DISEASES; QUINOLINES; SIRTUINS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954139965     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.7     Document Type: Review

References (160)

1. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 128(4), 635-638 (2007).
2. Mai A, Altucci L: Epi-drugs to fght cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 41(1), 199-213 (2009).
3. Mai A: The therapeutic uses of chromatin-modifying agents. Expert Opin. Ther. Targets 11(6), 835-851 (2007).
4. Manzo F, Tambaro FP, Mai A, Altucci L: Histone acetyltransferase inhibitors and preclinical studies. Expert Opin. Ther. Pat. 19(6), 761-774 (2009).
5. Rotili D, Simonetti G, Savarino A, Palamara AT, Migliaccio AR, Mai A: Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and b-hemoglobinopathies. Curr. Top. Med. Chem. 9(3), 272-291 (2009).
6. Spannhoff A, Hauser AT, Heinke R, Sippl W, Jung M: The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem 4(10), 1568-1582 (2009).
7. Spannhoff A, Sippl W, Jung M: Cancer treatment of the future: inhibitors of histone methyltransferases. Int. J. Biochem. Cell Biol. 41(1), 4-11 (2009).
8. Haberland M, Montgomery RL, Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10(1), 32-42 (2009).
9. Dekker FJ, Haisma HJ: Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14(19-20), 942-948 (2009).
10. Mai A, Rotili D, Valente S, Kazantsev AG: Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr. Pharm. Des. 15(34), 3940-3957 (2009).
11. Kouzarides T: Chromatin modifcations and their function. Cell 128(4), 693-705 (2007).
12. Cheung WL, Briggs SD, Allis CD: Acetylation and chromosomal functions. Curr. Opin. Cell Biol. 12(3), 326-333 (2000).
13. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389(6649), 349-352 (1997).
14. Clayton AL, Hazzalin CA, Mahadevan LC: Enhanced histone acetylation and transcription: a dynamic perspective. Mol. Cell 23(3), 289-296 (2006).
15. Shahbazian MD, Grunstein M: Functions of site-specifc histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007).
16. Ruthenburg AJ, Li H, Patel DJ, Allis CD: Multivalent engagement of chromatin modifcations by linked binding modules. Nat. Rev. Mol. Cell Biol. 8(12), 983-994 (2007).
17. Grozinger CM, Schreiber SL: Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 9(1), 3-16 (2002).
18. Mai A, Massa S, Rotili D et al.: Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25(3), 261-309 (2005).
19. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 89(3), 349-356 (1997).
20. Verdin E, Dequiedt F, Kasler HG: Class II histone deacetylases: versatile regulators. Trends Genet. 19(5), 286-293 (2003).
21. Martin M, Kettmann R, Dequiedt F: Class IIa histone deacetylases: regulating the regulators. Oncogene 26(37), 5450-5467 (2007).
22. Marks PA, Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 107(4), 600-608 (2009).
23. Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: what are the cancer relevant targets? Cancer Lett. 277(1), 8-21 (2009).
24. McKinsey TA, Zhang CL, Olson EN: MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27(1), 40-47 (2002).
25. Hubbert C, Guardiola A, Shao R et al.: HDAC6 is a microtubule-associated deacetylase. Nature 417(6887), 455-458 (2002).
26. Villagra A, Cheng F, Wang HW et al.: The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10(1), 92-100 (2009).
27. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
28. Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006).
29. Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene 26(37), 5420-5432 (2007).
30. Shankar S, Srivastava RK: Histone deacetylase inhibitors: mechanisms and clinical signifcance in cancer: HDAC inhibitor-induced apoptosis. Adv. Exp. Med. Biol. 615, 261-298 (2008).
31. Nervi C, Ferrara FF, Fanelli M et al.: Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARa fusion protein. Blood 92(7), 2244-2251 (1998).
32. Raelson JV, Nervi C, Rosenauer A et al.: The PML/RAR a oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88(8), 2826-2832 (1996).
33. Zhu J, Gianni M, Kopf E et al.: Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor a (RARa) and oncogenic RARa fusion proteins. Proc. Natl Acad. Sci. USA 96(26), 14807-14812 (1999).
34. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG: Constitutive degradation of PML/RARa through the proteasome pathway mediates retinoic acid resistance. Blood 93(5), 1477-1481 (1999).
35. Sternsdorf T, Puccetti E, Jensen K et al.: PIC-1/SUMO-1-modifed PML-retinoic acid receptor a mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol. Cell. Biol. 19(7), 5170-5178 (1999).
36. Muller S, Miller WH Jr, Dejean A: Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92(11), 4308-4316 (1998).
37. Jing Y: The PML-RARa fusion protein and targeted therapy for acute promyelocytic leukemia. Leuk. Lymphoma 45(4), 639-648 (2004).
38. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolf PP: Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARa and PLZF-RARa oncoproteins. Proc. Natl Acad. Sci. USA 97(18), 10173-10178 (2000).
39. Grignani F, De Matteis S, Nervi C et al.: Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia. Nature 391(6669), 815-818 (1998).
40. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA: Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol. Cell. Biol. 18(12), 7185-7191 (1998).
41. Finnin MS, Donigian JR, Cohen A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749), 188-193 (1999).
42. Somoza JR, Skene RJ, Katz BA et al.: Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12(7), 1325-1334 (2004).
43. Vannini A, Volpari C, Filocamo G et al.: Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101(42), 15064-15069 (2004).
44. Nielsen TK, Hildmann C, Dickmanns A, Schwienhorst A, Ficner R: Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 354(1), 107-120 (2005).
45. Bottomley MJ, Lo Surdo P, Di Giovine P et al.: Structural and functional ana lysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283(39), 26694-26704 (2008).
46. Furumai R, Matsuyama A, Kobashi N et al.: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002).
47. Wang DF, Helquist P, Wiech NL, Wiest O: Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 48(22), 6936-6947 (2005).
48. Weerasinghe SV, Estiu G, Wiest O, Pfum MK: Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors. J. Med. Chem. 51(18), 5542-5551 (2008).
49. Wang DF, Wiest O, Helquist P, Lan-Hargest HY, Wiech NL: On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J. Med. Chem. 47(13), 3409-3417 (2004).
50. Wang L, Luo HS, Xia H: Sodium butyrate induces human colon carcinoma HT-29 cell apoptosis through a mitochondrial pathway. J. Int. Med. Res. 37(3), 803-811 (2009).
51. Kortenhorst MS, Isharwal S, van Diest PJ et al.: Valproic acid causes dose-and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol. Cancer Ther. 8(4), 802-808 (2009).
52. Reid T, Valone F, Lipera W et al.: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 45(3), 381-386 (2004).
53. Khan N, Jeffers M, Kumar S et al.: Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409(2), 581-589 (2008).
54. Tomillero A, Moral MA: Gateways to clinical trials. Methods Find. Exp. Clin. Pharmacol. 31(9), 597-633 (2009).
55. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 3, 5 (2010).
56. Prince HM, Bishton MJ, Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 15(12), 3958-3969 (2009).
57. Piekarz RL, Bates SE: Epigenetic modifers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
58. Remiszewski SW, Sambucetti LC, Bair KW et al.: N-hydroxy-3-phenyl-2- propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl) [2-(1H-indol-3-yl)ethyl]amino]methyl] phenyl]-2-propenamide (NVP-LAQ824). J. Med. Chem. 46(21), 4609-4624 (2003).
59. Ocio EM, Vilanova D, Atadja P et al.: In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) (Epub ahead of print).
60. Steele NL, Plumb JA, Vidal L et al.: A Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008).
61. Galli M, Salmoiraghi S, Golay J et al.: A Phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 89(2), 185-190 (2010).
62. Itoh Y, Suzuki T, Miyata N: Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 14(6), 529-544 (2008).
63. Campas-Moya C: Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc.) 45(11), 787-795 (2009).
64. Piekarz RL, Frye R, Turner M et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
65. Suzuki T, Ando T, Tsuchiya K et al.: Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 42(15), 3001-3003 (1999).
66. Lucas DM, Davis ME, Parthun MR et al.: The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18(7), 1207-1214 (2004).
67. Nebbioso A, Clarke N, Voltz E et al.: Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77-84 (2005).
68. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R: Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67(11), 1182-1193 (2007).
69. Siu LL, Pili R, Duran I et al.: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 26(12), 1940-1947 (2008).
70. Garcia-Manero G, Assouline S, Cortes J et al.: Phase 1 study of the oral isotype specifc histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4), 981-989 (2008).
71. Blum KA, Advani A, Fernandez L et al.: Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br. J. Haematol. 147(4), 507-514 (2009).
72. Mai A, Valente S, Nebbioso A et al.: New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme-and cell-based investigations. Int. J. Biochem. Cell Biol. 41(1), 235-247 (2009).
73. Mai A, Massa S, Rotili D et al.: Synthesis and biological properties of novel, uracil-containing histone deacetylase inhibitors. J. Med. Chem. 49(20), 6046-6056 (2006). (Pubitemid 44484948)
74. Mai A, Massa S, Pezzi R, Valente S, Loidl P, Brosch G: Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 1(3), 245-254 (2005).
75. Illi B, Dello Russo C, Colussi C et al.: Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ. Res. 102(1), 51-58 (2008).
76. Inoue S, Mai A, Dyer MJ, Cohen GM: Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66(13), 6785-6792 (2006).
77. Mai A, Massa S, Pezzi R et al.: Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48(9), 3344-3353 (2005).
78. Nebbioso A, Manzo F, Miceli M et al.: Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 10(7), 776-782 (2009).
79. Duong V, Bret C, Altucci L et al.: Specifc activity of class II histone deacetylases in human breast cancer cells. Mol. Cancer Res. 6(12), 1908-1919 (2008).
80. Sambucetti LC, Fischer DD, Zabludoff S et al.: Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specifc chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274(49), 34940-34947 (1999).
81. Insinga A, Monestiroli S, Ronzoni S et al.: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11(1), 71-76 (2005).
82. Ruefi AA, Ausserlechner MJ, Bernhard D et al.: The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98(19), 10833-10838 (2001).
83. Vrana JA, Decker RH, Johnson CR et al.: Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18(50), 7016-7025 (1999).
84. Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4(1), 13-18 (2003).
85. Rossig L, Li H, Fisslthaler B et al.: Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91(9), 837-844 (2002).
86. Qian DZ, Kato Y, Shabbeer S et al.: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2), 634-642 (2006).
87. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N: Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65(23), 11136-11145 (2005).
88. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of g-H2AX foci and confnes HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 66(23), 11298-11304 (2006).
89. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74(5), 659-671 (2007).
90. Frew AJ, Johnstone RW, Bolden JE: Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 280(2), 125-133 (2009).
91. Lane AA, Chabner BA: Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
92. Maeda H, Bharate GY, Daruwalla J: Polymeric drugs for effcient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71(3), 409-419 (2009).
93. Darkin-Rattray SJ, Gurnett AM, Myers RW et al.: Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl Acad. Sci. USA 93(23), 13143-13147 (1996).
94. Han JW, Ahn SH, Park SH et al.: Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res. 60(21), 6068-6074 (2000).
95. Meinke PT, Colletti SL, Doss G et al.: Synthesis of apicidin-derived quinolone derivatives: parasite-selective histone deacetylase inhibitors and antiproliferative agents. J. Med. Chem. 43(25), 4919-4922 (2000).
96. Andrews KT, Walduck A, Kelso MJ, Fairlie DP, Saul A, Parsons PG: Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. Int. J. Parasitol. 30(6), 761-768 (2000).
97. Andrews KT, Tran TN, Lucke AJ et al.: Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob. Agents Chemother. 52(4), 1454-1461 (2008).
98. Dow GS, Chen Y, Andrews KT et al.: Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob. Agents Chemother. 52(10), 3467-3477 (2008).
99. Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP: A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum. J. Med. Chem. 51(12), 3437-3448 (2008).
100. Miller TA, Witter DJ, Belvedere S: Histone deacetylase inhibitors. J. Med. Chem. 46(24), 5097-5116 (2003).
101. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R: Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27(5), 359-366 (2006).
102. Klar AJ, Srikantha T, Soll DR: A histone deacetylation inhibitor and mutant promote colony-type switching of the human pathogen Candida albicans. Genetics 158(2), 919-924 (2001).
103. Smith WL, Edlind TD: Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob. Agents Chemother. 46(11), 3532-3539 (2002).
104. Mai A, Rotili D, Massa S et al.: Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg. Med. Chem. Lett. 17(5), 1221-1225 (2007).
105. Simonetti G, Passariello C, Rotili D, Mai A, Garaci E, Palamara AT: Histone deacetylase inhibitors may reduce pathogenicity and virulence in Candida albicans. FEMS Yeast Res. 7(8), 1371-1380 (2007).
106. Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ: Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J. Clin. Microbiol. 47(12), 3797-3804 (2009).
107. Demonte D, Quivy V, Colette Y, Van Lint C: Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem. Pharmacol. 68(6), 1231-1238 (2004).
108. Stevens M, De Clercq E, Balzarini J: The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med. Res. Rev. 26(5), 595-625 (2006).
109. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC: NF-kB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25(1), 139-149 (2006).
110. Jiang G, Espeseth A, Hazuda DJ, Margolis DM: c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodefciency virus type 1 promoter. J. Virol. 81(20), 10914-10923 (2007).
111. Lehrman G, Hogue IB, Palmer S et al.: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366(9485), 549-555 (2005).
112. Savarino A, Mai A, Norelli S et al.: 'Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 6, 52 (2009).
113. Ritchie D, Piekarz RL, Blombery P et al.: Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 94(11), 1618-1622 (2009).
114. Steffan JS, Bodai L, Pallos J et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857), 739-743 (2001).
115. Pallos J, Bodai L, Lukacsovich T et al.: Inhibition of specifc HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17(23), 3767-3775 (2008).
116. Bates EA, Victor M, Jones AK, Shi Y, Hart AC: Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26(10), 2830-2838 (2006).
117. Simonini MV, Camargo LM, Dong E et al.: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl Acad. Sci. USA 103(5), 1587-1592 (2006).
118. Ferrante RJ, Kubilus JK, Lee J et al.: Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23(28), 9418-9427 (2003).
119. Hockly E, Richon VM, Woodman B et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor defcits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100(4), 2041-2046 (2003).
120. Thomas EA, Coppola G, Desplats PA et al.: The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105(40), 15564-15569 (2008).
121. Schemies J, Sippl W, Jung M: Histone deacetylase inhibitors that target tubulin. Cancer Lett. 280(2), 222-232 (2009).
122. Pandey UB, Nie Z, Batlevi Y et al.: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447(7146), 859-863 (2007).
123. Irizarry MC, Growdon W, Gomez-Isla T et al.: Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain a-synuclein immunoreactivity. J. Neuropathol. Exp. Neurol. 57(4), 334-337 (1998).
124. Kontopoulos E, Parvin JD, Feany MB: a-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15(20), 3012-3023 (2006).
125. Leng Y, Chuang DM: Endogenous a-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J. Neurosci. 26(28), 7502-7512 (2006).
126. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM: Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2(10), 551-558 (2006).
127. Chou CJ, Herman D, Gottesfeld JM: Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 283(51), 35402-35409 (2008).
128. Rai M, Soragni E, Jenssen K et al.: HDAC inhibitors correct frataxin defciency in a Friedreich ataxia mouse model. PLoS ONE 3(4), E1958 (2008).
129. Xu C, Soragni E, Chou CJ et al.: Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem. Biol. 16(9), 980-989 (2009).
130. Michan S, Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem. J. 404(1), 1-13 (2007).
131. Finkel T, Deng CX, Mostoslavsky R: Recent progress in the biology and physiology of sirtuins. Nature 460(7255), 587-591 (2009).
132. +-dependent tubulin deacetylase. Mol. Cell 11(2), 437-444 (2003).
133. Vaquero A, Scher MB, Lee DH et al.: SIRT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev. 20(10), 1256-1261 (2006).
134. Blander G, Guarente L: The SIR2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435 (2004).
135. Bereshchenko OR, Gu W, Dalla-Favera R: Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32(4), 606-613 (2002).
136. Vaziri H, Dessain SK, Ng Eaton E et al.: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107(2), 149-159 (2001).
137. Bradbury CA, Khanim FL, Hayden R et al.: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19(10), 1751-1759 (2005).
138. Kuzmichev A, Margueron R, Vaquero A et al.: Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc. Natl Acad. Sci. USA 102(6), 1859-1864 (2005).
139. Yeung F, Hoberg JE, Ramsey CS et al.: Modulation of NF-kB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23(12), 2369-2380 (2004).
140. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL: Identifcation of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276(42), 38837-38843 (2001).
141. Ota H, Tokunaga E, Chang K et al.: SIRT1 inhibitor, sirtinol, induces senescencelike growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25(2), 176-185 (2006).
142. Mai A, Massa S, Lavu S et al.: Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (sirtuin) inhibitors. J. Med. Chem. 48(24), 7789-7795 (2005).
143. Lara E, Mai A, Calvanese V et al.: Salermide, a sirtuin inhibitor with a strong cancer-specifc proapoptotic effect. Oncogene 28(6), 781-791 (2009).
144. Napper AD, Hixon J, McDonagh T et al.: Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48(25), 8045-8054 (2005).
145. Solomon JM, Pasupuleti R, Xu L et al.: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26(1), 28-38 (2006).
146. Zhang Y, Zhang M, Dong H et al.: Deacetylation of cortactin by SIRT1 promotes cell migration. Oncogene 28(3), 445-460 (2009).
147. Heltweg B, Gatbonton T, Schuler AD et al.: Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 66(8), 4368-4377 (2006).
148. Lain S, Hollick JJ, Campbell J et al.: Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13(5), 454-463 (2008).
149. Outeiro TF, Kontopoulos E, Altmann SM et al.: Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837), 516-519 (2007).
150. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM: Aggresomes formed by a-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279(6), 4625-4631 (2004).
151. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A: Opposing activities protect against age-onset proteotoxicity. Science 313(5793), 1604-1610 (2006).
152. Suzuki K, Koike T: Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 147(3), 599-612 (2007).
153. Goedert M, Spillantini MG: A century of Alzheimer's disease. Science 314(5800), 777-781 (2006).
154. Outeiro TF, Marques O, Kazantsev A: Therapeutic role of sirtuins in neurodegenerative disease. Biochim. Biophys. Acta 1782(6), 363-369 (2008).
155. Kim D, Nguyen MD, Dobbin MM et al.: SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26(13), 3169-3179 (2007).
156. Marambaud P, Zhao H, Davies P: Resveratrol promotes clearance of Alzheimer's disease amyloid-b peptides. J. Biol. Chem. 280(45), 37377-37382 (2005).
157. Gan L, Mucke L: Paths of convergence: sirtuins in aging and neurodegeneration. Neuron 58(1), 10-14 (2008).
158. Chen J, Zhou Y, Mueller-Steiner S et al.: SIRT1 protects against microglia-dependent amyloid-b toxicity through inhibiting NF-kB signaling. J. Biol. Chem. 280(48), 40364-40374 (2005).
159. Binda O, Nassif C, Branton PE: SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 27(24), 3384-3392 (2008).
160. Luo Y, Jian W, Stavreva D et al.: Trans-regulation of histone deacetylase activities through acetylation. J. Biol. Chem. 284(50), 34901-34910 (2009).